We have observed that wall motion abnormalities (WMAs) during exercise echocardiography (ExE) are associated to events in hypertrophic cardiomyopathy (HCM). Our objective was to evaluate ExE and cardiac magnetic resonance (CMR) to predict outcome in HCM.
Introduction
Several risk factors have been proposed to predict outcome in hypertrophic cardiomyopathy (HCM). 1 Other likely risk factors have lately emerged like increased fibrosis demonstrated by cardiac magnetic resonance (CMR). 2, 3 Our group has also demonstrated that patients with HCM who develop wall motion abnormalities (WMAs) during exercise echocardiography (ExE) are at higher risk. 4 The aims of this study were to evaluate ExE and CMR to predict outcome in HCM and to explore the relationships between both techniques.
Methods Patients
A group of 160 patients with clinical diagnosis of HCM which was being followed-up in our HCM unit and were referred for ExE and CMR according to a research protocol was considered. HCM was diagnosed by the presence of a non-dilated and hypertrophied left ventricle (LV) (wall thickness .15 mm in adult index patients or .13 mm plus abnormal electrocardiographic results in relatives) in the absence of another cardiac or systemic disease capable of producing the magnitude of LV † Partially presented in the European Society of Cardiology Congress 2013, Amsterdam, The Netherlands.
hypertrophy observed. 1, 5 Patients with LV systolic dysfunction, defined as a resting LV ejection fraction (LVEF) ,50% (n ¼ 9), and patients who had either a history of coronary disease or evidence of coronary lesions on angiography (n ¼ 3) were excluded. The final study group consisted of 148 patients (122 index patients and 26 affected relatives). These patients represent a subset of a group of 239 patients with HCM who underwent ExE and had their data previously published. 4 ExE and CMR were performed without knowledge of the other test results. Decisions regarding coronary angiographies were performed according to the responsible team. Informed consent was obtained for each patient.
Exercise echocardiography
Medications were not withdrawn before ExE. Patients were encouraged to perform a treadmill exercise test (Bruce protocol 86%, other protocols 14%). Heart rate, blood pressure (BP), and a 12-lead electrocardiogram were obtained at baseline and at each stage of the protocols. End points included significant arrhythmia, severe hypertension (systolic BP .240 mmHg or diastolic BP .110 mmHg), hypotensive response (decrease .20 mmHg from baseline), or limiting symptoms. Two-dimensional echocardiography (Vivid 5, GE, Horten, Norway) was performed in standard views, at baseline and peak exercise. 4, 6 Peak ExE was performed when signs of exhaustion were present or an end point was reached. Left ventricular outflow tract and intra-ventricular gradients (mmHg) and mitral regurgitation (MR) were measured at rest and during the post-exercise period (1 min ), as described. 7 Significant MR was defined as greater than or equal to moderate MR. Abnormal BP response was defined as a failure to increase systolic BP at least 20 mmHg during exercise or an initial increase with a subsequent fall of 20 mmHg. 8 
ExE analysis
LVEF at rest and at exercise were measured by the biplane Simpson's rule. 9 The LV was divided into 16 segments. 10 A wall motion score index (WMSI) at rest and at exercise was calculated, with normal wall motion scoring ¼ 1, hypokinetic ¼ 2, akinetic ¼ 3, and dyskinetic ¼ 4. A WMSI . 1 defined the presence of WMAs. Inter-and intra-observer variabilities for the assessment of WMAs in patients with HCM have been previously reported by our group. 4 
Cardiac magnetic resonance
Images were obtained with a 1.5-T system (Gyroscan NT Intera or Achieva; Philips Medical Systems, Best, The Netherlands) in conjunction with a phased-array body coil and ECG gating. Perfusion images were acquired in the short-axis plane from base to apex with an ECG-triggered T1-weighted inversion-recovery sequence (repetition time/echo time, 3.2/1.6 ms; flip angle, 508; FOV, 400 mm; voxel size, 3.12 × 3.25; section thickness, 8 mm). Gadopentetate dimeglumine, 0.05 mmol/kg of body weight (Dotarem, Guerbet, France), was injected at 4 mL/s and flushed with 20-25 mL of normal saline solution using a power injector. Forty dynamic scans were acquired simultaneously at each slice during the first pass of the contrast agent. 11 Patients were instructed to hold their breath as long as possible and to breathe quietly when necessary. After the series of perfusion images was completed, another bolus of gadopentetate dimeglumine, 0.15 mmol/kg, was injected until achievement of a total dose of 0.2 mmol/kg for late gadolinium enhancement (LGE).
LGE images were acquired 10 min after the injection of the contrast material with an inversion-recovery T1-weighted sequence 12, 13 (repetition time/echo time, 4.1/1.35 ms; inversion time, 200 -400 ms), adjusted for each patient to achieve optimal suppression of normal myocardium; flip angle, 158; FOV, 400 mm; voxel size, 1.66 × 1.85; and section thickness, 8 mm. Three series were acquired in the short axis, at the base, midventricle, and apex; and one series in the two-and four-chamber views.
CMR imaging analysis
Images were analysed with image post-processing software (Viewforum, version 5.0; Philips Medical Systems) by two experienced radiologists, whose joint opinion was reached.
LGE was considered present when the myocardial signal intensity was highly hyperintense and persists in the same slice after swapping the phase encoding, to exclude artefacts.
LGE was then quantified with the QMass MR w software, version 7.1 (Medis medical imaging systems, Leiden, The Netherlands) and expressed as a percentage of the total LV mass. Signal intensity was measured as mean intensity plus standard deviations (SD) of mean for intra-individual analysis. Enhancement was defined as signal intensity .5 SD above the acquired mean signal intensity level.
Follow-up
Follow-up and events were determined by revisiting the patients and reviewing medical records and death certificates. No patients were lost during follow-up. Hard events (Hard-E) included cardiac death, cardiac transplantation, appropriate defibrillator discharge, sustained ventricular tachycardia (VT), stroke in the context of atrial fibrillation/flutter, myocardial infarction, and heart failure requiring hospitalization. Cardiac death was defined as death due to acute myocardial infarction, congestive heart failure, life-threatening arrhythmias, or cardiac arrest; unexpected, otherwise unexplained sudden death was also considered cardiac death. Combined events (Comb-E) were defined as a Hard-E or new onset atrial fibrillation or syncope. Myectomy, septal ablation, defibrillator implantation, and demonstration of non-sustained VT (NSVT) were not considered events.
Statistical analysis
Continuous variables were reported as mean + 1 SD for those following a normal distribution and as median and inter-quartile range for those following a non-normal distribution. Inter-group comparisons were performed by the Student t-test or the Mann-Whitney test as appropriate. Categorical variables were reported as percentages and inter-group comparisons performed by the x 2 or the Fisher exact tests. Event-free survival was estimated by the Kaplan-Meier method. Patients who died of non-cardiac causes were censored at the time of death. Univariable associations of variables with events were assessed with the Cox proportional hazards model. A P-value of ,0.05 was considered significant. Hazard ratios (HR) and 95% confidence intervals (CI) are given.
Variables significantly associated to the end points in the univariable analyses were entered in a multivariable model. The value of ExE and CMR over clinical and exercise testing data was assessed by steps. The first step was based on clinical data and resting echocardiography. In the second step, the exercise testing variables were added. The third step consisted of the addition of ExE variables. In the final step, the CMR data were introduced. Continuous variables were used instead of dichotomous variables with similar meaning. Also, in case of variables with similar meaning, those with higher area under the receiver operator curves were chosen. To explore whether ExE and CMR provide incremental prognostic information compared with other established markers of adverse outcome in HCM, we also assessed three models in which we included the clinical predictors in step 1, then resting LVEF in step 2, and then increase in WMSI in step 3 for Model 1; % of the total LV mass with LGE for Model 2; and perfusion defect area for Model 3. Clinical variables in step 1 in these models were family history of sudden death, previous cardiac arrest or history of sustained VT, documented NSVT, previous syncope, blunted BP during exercise, maximal wall thickness, and resting left ventricular outflow tract (LVOT) obstruction. The incremental value between steps was measured by the x 2 method. Kaplan-Meier curves for the prediction of Comb-E, based on the presence or absence of exercise WMAs and the presence or absence of LGE, were generated.
Results Tables 1 and 2 show the baseline characteristics and resting and ExE parameters.
Exercise echocardiography
ExE was performed without complications. Exhaustion was the more common reason for stopping the test (86.5%). Faintness and hypotension were the reasons for ceasing exercise in four patients. Six patients experienced dyspnoea and 12 angina.
Exercise WMAs and associations
Exercise WMAs occurred in 13 patients (8.8%) and were more frequent in patients with events (Hard-E: 57 vs. 6%, P ¼ 0.001; Comb-E: 23 vs. 6%, P ¼ 0.005). These WMAs were described as global phenomena in 3 patients and as regional phenomena in 10, involving predominantly the antero-septal region (9/10). Coronary angiographies performed in 9/13 patients with exercise WMAs and in 18/135 patients without WMAs showed the absence of coronary lesions. A hypotensive response was not different among patients with or without exercise WMAs (46 vs. 33%), as it was the presence of significant MR at rest (15 vs. 16%) or at exercise (38 vs. 23%). LV wall thickness and left atrial diameter were also similar in patients with and without exercise WMAs (19 + 6 vs. 20+ 5 mm and 44 + 6 vs. 44 + 6 mm, respectively). Left ventricular outflow tract gradients at exercise were lower in patients with WMAs (10, 10-21, vs. 30, 10-100 mmHg, P ¼ 0.02). LVEF was also lower at rest and at exercise in patients with exercise WMAs (65 + 10 vs. 71 + 9 and 63 + 8 vs. 74+ 10, P ¼ 0.01 and P , 0.001, respectively), as it was exercise workload (8.5 + 2.3 vs. 10.5 + 3.3 METs, P ¼ 0.04).
Peak WMSI correlated weakly with myocardial mass with LGE (r ¼ 0.20, P ¼ 0.02) and moderately with perfusion defect area (r ¼ 0.40, P , 0.001). Although there were no significant differences in LGE expressed as absolute or relative values between patients with and without exercise WMAs 
CMR imaging and associations
Ten patients (6.8%) had a perfusion defect (range: 0.5-17% of the myocardium) and 48 (32.4%) had LGE (range: 5-46% of the LV mass). Tables 4 and 5 depict CMR data in patients with and without Hard-E and Comb-E, respectively. CMR data exhibited a trend to be worse in patients with Hard-E than in those without. In contrast, CMR data were definitively worse in patients with Comb-E than in those without. Univariable associates of LGE were wall thickness (P , 0.001), left atrium diameter (P ¼ 0.01), ST-segment abnormalities on resting ECG (P ¼ 0.005), and lack of treatment with angiotensin receptor blockers/angiotensin-converting enzyme inhibitors (P ¼ 0.047). On multivariable analysis, only maximal wall thickness was associated to LGE (OR 1.10, 95% CI 1.02-1.19, P ¼ 0.02). On the other hand, a LGE signal affecting 15% of the LV mass was associated to left atrium diameter (P ¼ 0.03), a history of NSVT (P ¼ 0.03), lower LV gradient at exercise (P ¼ 0.04), exercise WMAs (P ¼ 0.009), and peak WMSI (P ¼ 0.008) by univariable analysis. Both left atrium diameter and LVOT gradient at exercise remained independently associated with an extensive LGE (OR 1.12, 95% CI 1.03 -1.22, P ¼ 0.01; OR 0.99, 95% CI 0.97-1.00, P ¼ 0.04, respectively), whereas the presence of exercise WMAs exhibited a trend towards this association (P ¼ 0.085).
Events
During a follow-up of 7.1 + 2.7 years, 7 patients had a Hard-E (4 admissions due to cardiac failure, 2 strokes, 1 discharge of defibrillator) and 26 had a Comb-E (7 Hard-E, 12 new atrial fibrillation, 7 syncope). Univariable predictors of Hard-E were beta-blocker therapy (HR ¼ 4.53, 95% CI ¼ 1.01-20.3, P ¼ 0.049), peak double product (Pk-DP) (HR ¼ 0.99, 95% CI ¼ 0.99-0.99, P ¼ 0.04), % achieved of the maximal age-predicted heart rate (HR ¼ 0.03, 95% CI ¼ 0.00-0.68, P ¼ 0.04), D in WMSI (HR ¼ 220, 95% CI ¼ 4 -13100, P ¼ 0.01), perfusion defect area (HR ¼ 1.16, 95% CI ¼ 1.03 -1.31, P ¼ 0.02), and myocardial mass with LGE. (HR ¼ 1.07, 95% CI ¼ 1.01-1.13, P ¼ 0.03). No further analysis was performed due to the limited number of patients with Hard-E. Univariable and multivariable predictors of Comb-E are listed in Table 6 . After adjustment, Pk-DP and DWMSI remained independent predictors, whereas LGE expressed as a percentage of the total LV mass exhibited a trend to be significant. were only performed in four patients who did not have events and in one who had a Comb-E, and defibrillator implantation in six and four patients without and with Hard-E, respectively. Figure 3 shows Kaplan-Meier curves according to the presence or absence of exercise WMAs and of LGE. The worst outcome was found in patients with positive results by both techniques. ExE data (DWMSI) and perfusion defect area by CMR increased the value of clinical risk factors and resting LVEF for predicting events, whereas LGE expressed as a percentage of the total LV showed a trend to increase the value of these variables for predicting events ( Figure 4 ).
Discussion
In this observational study of 148 patients with HCM who were evaluated by ExE and CMR, 8.8% of the patients had exercise WMAs, 6.8% had perfusion defects, and 32.4% LGE, although an extensive involvement was observed in only 14.2%. Pk-DP and D in WMSI remained independent predictors of Comb-E, whereas there was a trend for LGE expressed as a percentage of the LV mass to be a predictor.
Previous studies with CMR
LGE has been found previously in more than half of the patients with HCM 2,3,14 -16 which is higher than in the current research, likely because we excluded patients with LV systolic dysfunction and with coronary artery disease. In one study, HCM patients at high risk according to clinical predictors had more frequent LGE signal and LV systolic dysfunction. 14 Also, Rubinshtein et al. 16 showed that independent associates of LGE were depressed LVEF and increased septal thickness. Fibrosis enhancement has been found to be associated to overall mortality 2 and to malignant arrhythmias in HCM. 3 We hypothesize that the presence of myocardial fibrosis might impair LV response to exercise, therefore explaining the associations between exercise WMAs and abnormal CMR.
LV dysfunction during exercise
Myocardial ischaemia, LV diastolic dysfunction, LVOT obstruction, or impaired inotropic reserve might explain the occurrence of WMAs. Myocardial ischaemia is the explanation suggested in many studies that evaluated HCM patients by radionuclides during exercise. ; systolic frames in these same views at the bottom. Supplementary data online, Video S1 correspond to the exercise echocardiography study of this patient.
Exercise echo and cardiac magnetic resonance in HCM On the other hand, we did not observe an association between exercise WMAs and LVOT obstruction. Okeie et al. 18 also failed to find an association between LV function and obstruction during stress, whereas others found this association in a small series of patients. 20 However, patients with resting LVOT obstruction were excluded in most of the studies that measured LV systolic function during exercise. 8, 17, 18 The frequency of LV systolic dysfunction during exercise in HCM ranges from 8 to 43%. 17, 18 Centres admitting the most symptomatic patients might detect the highest number. In addition, exercise LV dysfunction may be more prevalent in certain genetic disorders like troponin gene mutations. 21 Finally, although not explored in this research, other methods to evaluate myocardial function during exercise such as speckle tracking might predict outcome. In this regard,
LGE has been recently found to be associated to depressed longitudinal function during exercise in patients with HCM. 22 In a previous ExE study by our group that included 239 patients with HCM, the frequency of exercise WMAs was 7.9%, 4 which is similar to the actual report. ExE predicted worse outcome in this previous report. In the current analysis, ExE maintained its power to predict events, whereas CMR data exhibited a trend to be associated to poorer outcome.
LVOT obstruction
Although LVOT obstruction may correlate with symptoms and response to exercise, we did not find an association between exercise LVOT obstruction and exercise WMAs, nor between LVOT obstruction and events. There have been conflicting results regarding the association between LVOT obstruction and events with studies that have found a higher probability of events in patients with LVOT obstruction 23 and others that have not. 24 Currently, a LVOT gradient ≥30 mmHg is considered a secondary marker for events. 1 
Limitations
As in many studies dealing with outcome in HCM, the main limitation is the reduced number of events. This is particularly true for this Figure 2 Abnormal cardiac magnetic resonance (A -C) and abnormal LV response to exercise in a patient with hypertrophic cardiomyopathy.
Late gadolinium enhancement signals are seen in the three short-axis views (A -C). The resting echocardiographic study was normal (D), whereas during exercise, extensive wall motion abnormalities developed (E). Diastolic frames in the four-chamber apical and long-axis views are shown on the top of each stage (rest and exercise); systolic frames in these same views at the bottom. Supplementary data online, Video S2 correspond to the exercise echocardiography study of this patient. study, as we excluded patients with LV systolic dysfunction, who are already at higher risk.
Another limitation is the semi-quantitative method employed to assess LGE and perfusion by CMR, as only five planes were used. The patchy pattern of fibrosis in HCM may have avoided the detection of LGE in some of our patients. However, this was the only method available at the time we began with this study.
Coronary angiographies were not performed in 4 of the 13 patients with exercise WMAs. Although the pre-test probability of . coronary artery disease was low or very low in these four patients, this entity could not be entirely ruled out. Outcome in HCM has been assessed by other methods. A restrictive LV inflow pattern was a predictor of death in one study. 25 Unfortunately, assessment of LV inflow was not available for all the patients included in our study. Left atrium volume has been also recognized as a predictor of unfavourable outcome in HCM. 26 MR assessment by colour Doppler has many limitations. Among them, colour assessment is affected by gain, filter settings, transducer frequency, and frame rate. 27 Furthermore, quantitative assessment is a challenge in HCM patients as the MR proximal isovelocity area appears mixed with the LVOT high velocity jet. The ExE results were available to the responsible clinicians and may have influenced therapy. Patients with LVOT obstruction were more likely to undergo septal ablation or myectomy. These procedures might have influenced outcome and therefore limited the potential prognostic value of LVOT obstruction. HR, hazard ratio; CI, confidence interval; MAPHR, maximal age-predicted heart rate WMSI, wall motion score index; LGE, late gadolinium enhancement. * Other non-significant analysed variables were age, gender, family history of sudden death, family history of HCM, history of atrial fibrillation, history of non-sustained ventricular tachycardia or sudden cardiac death, current atrial fibrillation, history of syncope, treatment with calcium channel blockers, treatment with disopyramide, treatment with amiodarone, treatment with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors, maximal LV thickness, presence of resting ECG abnormalities, positive ECG exercise testing, metabolic equivalents, LVEF either at rest or at exercise, resting LVOT gradient, exercise LVOT gradient, significant mitral regurgitation either at rest or at exercise, and number of risk factors. further stratify patients over traditional risk assessment deserves further research.
Clinical implications

